Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436488 | 1.00 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL4755970 | 1.00 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5448092 | 1.00 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5441719 | 1.00 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5458824 | 1.00 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL4755975 | 1.00 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5446651 | 0.90 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5447752 | 0.90 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5436131 | 0.90 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5437186 | 0.90 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1572184-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004054564-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885USP2 4327/4885ALDH1A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.